Anne Anne Kerbrat

Prof. Anne Anne Kerbrat

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2020 in Brain
Verified
Journal Article
Open access
PDF file
AKAnne Anne Kerbrat
Anne Anne Kerbrat
CGCharley Gros
Charley Gros
ABAtef Badji
Atef Badji
EBElise Bannier
Elise Bannier
FGFrancesca Galassi
Francesca Galassi
JCJulien Cohen-Adad
Julien Cohen-Adad
Despite important efforts to solve the clinico-radiological paradox, correlation between lesion load and physical disability in patients with multiple sclerosis remains modest. One hypothesis could be that lesion location in corticospinal tracts plays a key role in explaining motor impairment. In this study, we describe the distribution of lesions along the corticospinal tracts from the cortex to the cervical spinal cord in patients with various disease phenotypes and disability status. We also assess the link between lesion load and location within corticospinal tracts, and disability at baseline and 2-year follow-up. We retrospectively included 290 patients (22 clinically isolated syndrome, 198 relapsing remitting, 39 secondary progressive, 31 primary progressive multiple sclerosis) from eight sites. Lesions were segmented on both brain (T2-FLAIR or T2-weighted) and cervical (axial T2- or T2*-weighted) MRI scans. Data were processed using an automated and publicly available pipeline. Brain, brainstem and spinal cord portions of the corticospinal tracts were identified using probabilistic atlases to measure the lesion volume fraction. Lesion frequency maps were produced for each phenotype and disability scores assessed with Expanded Disability Status Scale score and pyramidal functional system score. Results show that lesions were not homogeneously distributed along the corticospinal tracts, with the highest lesion frequency in the corona radiata and between C2 and C4 vertebral levels. The lesion volume fraction in the corticospinal tracts was higher in secondary and primary progressive patients (mean = 3.6 ± 2.7% and 2.9 ± 2.4%), compared to relapsing-remitting patients (1.6 ± 2.1%, both P < 0.0001). Voxel-wise analyses confirmed that lesion frequency was higher in progressive compared to relapsing-remitting patients, with significant bilateral clusters in the spinal cord corticospinal tracts (P < 0.01). The baseline Expanded Disability Status Scale score was associated with lesion volume fraction within the brain (r = 0.31, P < 0.0001), brainstem (r = 0.45, P < 0.0001) and spinal cord (r = 0.57, P < 0.0001) corticospinal tracts. The spinal cord corticospinal tracts lesion volume fraction remained the strongest factor in the multiple linear regression model, independently from cord atrophy. Baseline spinal cord corticospinal tracts lesion volume fraction was also associated with disability progression at 2-year follow-up (P = 0.003). Our results suggest a cumulative effect of lesions within the corticospinal tracts along the brain, brainstem and spinal cord portions to explain physical disability in multiple sclerosis patients, with a predominant impact of intramedullary lesions.

1 May 2024 in JAMA Neurology
Verified
Journal Article
Closed access
PDF file
GJGuillaume Jouvenot
Guillaume Jouvenot
GCGuilhem Courbon
Guilhem Courbon
MLMathilde Lefort
Mathilde Lefort
FRFabien Rollot
Fabien Rollot
RCRomain Casey
Romain Casey
NMNicolas Maubeuge
Nicolas Maubeuge
Importance: A recent randomized clinical trial concluded that discontinuing medium-efficacy therapy might be a reasonable option for older patients with nonactive multiple sclerosis (MS), but there is a lack of data on discontinuing high-efficacy therapy (HET). In younger patients, the discontinuation of natalizumab and fingolimod is associated with a risk of rebound of disease activity.Objective: To determine whether discontinuing HET in patients 50 years and older with nonactive MS is associated with an increased risk of relapse compared with continuing HET.Design, Setting, and Participants: This observational cohort study used data from 38 referral centers from the French MS registry (Observatoire Français de la Sclérose en Plaques [OFSEP] database). Among 84704 patients in the database, data were extracted for 1857 patients 50 years and older with relapsing-remitting MS treated by HET and with no relapse or magnetic resonance imaging activity for at least 2 years. After verification of the medical records, 1620 patients were classified as having discontinued HET or having remained taking treatment and were matched 1:1 using a dynamic propensity score (including age, sex, disease phenotype, disability, treatment of interest, and time since last inflammatory activity). Patients were included from February 2008 to November 2021, with a mean (SD) follow-up of 5.1 (2.9) years. Data were extracted in June 2022.Exposures: Natalizumab, fingolimod, rituximab, and ocrelizumab.Main Outcomes and Measures: Time to first relapse.Results: Of 1620 included patients, 1175 (72.5%) were female, and the mean (SD) age was 54.7 (4.8) years. Among the 1452 in the HET continuation group and 168 in the HET discontinuation group, 154 patients in each group were matched using propensity scores (mean [SD] age, 57.7 [5.5] years; mean [SD] delay since the last inflammatory activity, 5.6 [3.8] years; mean [SD] follow-up duration after propensity score matching, 2.5 [2.1] years). Time to first relapse was significantly reduced in the HET discontinuation group compared with the HET continuation group (hazard ratio, 4.1; 95% CI, 2.0-8.5; P < .001) but differed between HETs, with a hazard ratio of 7.2 (95% CI, 2.1-24.5; P = .001) for natalizumab, 4.5 (95% CI, 1.3-15.5; P = .02) for fingolimod, and 1.1 (95% CI, 0.3-4.8; P = .85) for anti-CD20 therapy.Conclusion and Relevance: As in younger patients, in patients 50 years and older with nonactive MS, the risk of relapse increased significantly after stopping HETs that impact immune cell trafficking (natalizumab and fingolimod). There was no significant increase in risk after stopping HETs that deplete B-cells (anti-CD20 therapy). This result may inform decisions about stopping HETs in clinical practice.

1 March 2025 in Neurology Neuroimmunology & Neuroinflammation
Verified
Journal Article
Open access
MMMarie Mainguy
Marie Mainguy
RCRomain Casey
Romain Casey
SVSandra Vukusic
Sandra Vukusic
CLChristine Lebrun-Frenay
Christine Lebrun-Frenay
EBEric Berger
Eric Berger
DLDavid-Axel Laplaud
David-Axel Laplaud
Older studies reported an increased risk of relapse after in vitro fertilization (IVF) in women with multiple sclerosis (MS), which has not been confirmed by more recent works. All these studies had several limitations, such as small sample sizes, absence of a control population, or lack of neurologic validation of the relapses. The aim of this study was to determine the risk of relapse after IVF in women with MS. This retrospective cohort study included all women with MS who underwent IVF between 2009 and 2019 and a control group of women with MS who did not undergo IVF matched on age, MS duration, number of relapses, and MS-specific treatments in the previous year. Data on MS (disease duration, treatments, and relapses) were from the French MS Registry (OFSEP), whereas data on IVF (number of procedures, stimulation protocol type, and outcomes) were from the French national health insurance database. For this, the 2 databases were linked by indirect matching. In total, 115 women with MS underwent 199 IVF procedures (mean age at first IVF: 33.9 ± 4.0 years; 45.2% had ≥2 IVF procedures), and 175 IVFs (88.0%) could be matched to specific patients. The risk of relapse in the 3 months after index date was the same in both IVF group and control group (0.06 relapse per patient-year), as confirmed also by the before-after analysis in the IVF group (0.06 vs 0.08). This study, using a 10-year clinical and administrative dataset, did not find any increased risk of relapse after IVF. The maintenance of disease-modifying therapies until IVF was a determining factor in reducing the risk of relapse.

5 April 2025 in Journal of Neurology
Verified
Journal Article
Open access
PDF file
JHJérémy Hong
Jérémy Hong
MGMalo Gaubert
Malo Gaubert
MLMathilde Lefort
Mathilde Lefort
JFJean Christophe Ferré
Jean Christophe Ferré
EPEmmanuelle Le Page
Emmanuelle Le Page
AKAnne Anne Kerbrat
Anne Anne Kerbrat
Background: The utility of systematic spinal cord (SC) MRI for monitoring disease activity after a multiple sclerosis (MS) diagnosis remains a topic of debate. Objectives: To evaluate the frequency of disease activity when considering brain MRI alone versus both brain and SC MRI and to identify factors associated with the occurrence of new SC lesions. Methods: We conducted a retrospective analysis of clinical and imaging data prospectively collected over 5 years as part of the EMISEP cohort study. A total of 221 intervals (with both brain and spinal cord MRI scans available at 2 consecutive time-points) from 68 patients were analysed. For each interval, brain (3D Fluid-Attenuated Inversion Recovery (FLAIR, axial T2 and axial PD) and SC MRI (sagittal T2 and phase-sensitive inversion recovery, axial T2*w and 3D T1) were reviewed to detect new lesions. Each interval was classified as symptomatic (with relapse) or asymptomatic. The baseline brain and SC lesion numbers were computed. Results: SC MRI activity without clinical relapse and/or brain MRI activity was rare (4 out of 221 intervals, 2%). The occurrence of a new SC lesion was associated with the number of brain lesions at baseline (OR = 1.002 [1.000; 1.0004], p = 0.015) and the occurrence of a new brain lesion during the interval (OR = 1.170 [1.041; 1.314], p = 0.009), but not with the baseline SC lesion number (p = 0.6). Conclusion: These findings support the current guidelines recommending routine disease monitoring with brain MRI alone, even in patients with a high SC lesion load.

12 August 2025 in Neurology
Verified
Journal Article
Closed access
CRCamille Robin
Camille Robin
FRFabien Rollot
Fabien Rollot
MLMathilde Lefort
Mathilde Lefort
RCRomain Casey
Romain Casey
SVSandra Vukusic
Sandra Vukusic
AIas the OFSEP Investigators
as the OFSEP Investigators
The therapeutic strategy in patients with late-onset MS (LOMS) remains poorly defined. In this study, we aimed to evaluate both clinical and MRI outcomes between 2 cohorts of patients with relapsing-remitting LOMS treated or not yet treated. Patients with relapsing-remitting MS were included for the analysis if disease onset occurred after 55 years and if they had at least one follow-up visit. The primary outcome was time to first relapse between 2 matched groups of patients with LOMS (treated and not yet treated). Secondary outcomes were as follows: (1) time to first confirmed disability progression (CDP), (2) time to first progression independent of relapse activity (PIRA) event, (3) time to secondary progression (SPMS), (4) time to first MRI activity, and (5) serious infection incidence rates (IIRs). For the comparative analyses, we adopted a time-dependent propensity score matching approach. A total of 881 patients fulfilled the inclusion criteria. The mean (SD) age at onset was 59.9 (4.43) years. After applying propensity score matching, 436 patients were matched. The mean (SD) follow-up duration was 5.2 (4.27) years in the treated group and 5.0 (3.86) years in the not-yet-treated group. Mean (SD) time to first relapse was significantly longer in the treated group compared with the not-yet-treated group (7.0 years [0.33] vs 5.4 years [0.33]; p = 0.001). Mean (SD) time to first MRI activity was significantly longer in the treated group (5.9 years [0.33] vs 5.0 years [0.33]; p = 0.049). However, the mean time to CDP, PIRA, or SPMS was not different between the 2 groups (difference = 0.32 years; p = 0.585 for CDP; difference = 0.40 years; p = 0.442 for PIRA; difference = -0.02 years; p = 0.952 for SPMS). No increase in serious IIRs was observed with an incidence rate ratio of 0.38 (95% CI 0.07-2.10, p = 0.265) in the never-treated group compared with the treated one. This study demonstrates a beneficial effect of disease-modifying therapy (DMT) on disease activity in patients with LOMS but without significant impact on disability progression. Main limitations are linked to the challenge of data collection and to the baseline imbalances between the 2 groups. This study provides Class III evidence that in patients with LOMS, treatment with DMTs is associated with a longer time to first relapse compared with those not treated with DMTs.

14 October 2020 in Revue Neurologique
Verified
Journal Article
Closed access
SLS. Leguy
S. Leguy
BCB. Combès
B. Combès
EBE. Bannier
E. Bannier
AKAnne Anne Kerbrat
Anne Anne Kerbrat